In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring

Annals of Clinical Biochemistry

Volumn 42, Issue 2, 2005, Pages 149-152

  Fenwick, Sean ^a   Roberts, Edward A ^a   Mahesh, Balakrishna S ^a   Roberts, Norman B ^a  

^a ROYAL LIVERPOOL AND BROADGREEN UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; ALUMINUM HYDROXIDE; C REACTIVE PROTEIN; ERYTHROPOIETIN; PHOSPHATE BINDING AGENT;

AGED; AGITATION; ALUMINUM BLOOD LEVEL; ALUMINUM OVERLOAD; ARTICLE; BACTEREMIA; CASE REPORT; COGNITIVE DEFECT; CONSCIOUSNESS DISORDER; CYTOTOXICITY; HEMODIALYSIS; HUMAN; INFECTION; KIDNEY FAILURE; MALE; NEUROTOXICITY; PATIENT MONITORING; PRIORITY JOURNAL; REFRACTORY ANEMIA;

AGED; ALUMINUM; ALUMINUM HYDROXIDE; DRUG COMBINATIONS; HUMANS; INFECTION; KIDNEY FAILURE, CHRONIC; MAGNESIUM HYDROXIDE; MALE; NERVOUS SYSTEM DISEASES; RENAL DIALYSIS;

EID: 17144363971     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/0004563053492757     Document Type: Article

References (21)

1. Parkinson IS, Ward MK, Kerr DNS. Dialysis encephalopathy, bone disease and anaemia: the aluminium intoxication syndrome during regular haemodialysis. J Clin Path 1981; 34: 1285-94
2. Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol Dial Transplant 2002; 17(Suppl. 2): 9-12
3. Malluche HH. Aluminium and bone disease in chronic renal failure. Nephrol Dial Transplant 2002; 117: 21-4
4. Touam M, Martinez F, Lacour B, et al. Aluminium-induced, reversible microcytic anemia in chronic renal failure: clinical and experimental studies. Clin Nephrol 1983; 19: 295-8
5. Alfrey AC, LeGendre GR, Kaehny WD. The dialysis encephalopathy syndrome. Possible aluminium intoxication. N Engl J Med 1976; 294: 184-8
6. de Wolff FA, Berend K, Van der Voet GB. Subacute fatal aluminum poisoning in dialyzed patients: post-mortem toxicological findings. Forensic Sci Int 2002; 128: 41-3
7. Andreoli SP, Dunson JW, Bergstein JM. Calcium carbonate is an effective phosphorus binder in children with chronic renal failure. Am J Kid Dis 1987; 9: 206-10
8. Fukagawa M, Junichiro J, Kurokawa K, Kurokawa K. Renal osteodystrophy and secondary hyperparathyroidism. Nephrol Dial Transplant 2002; 17: 2-6
9. Roberts NB, Clough A, Bellia JP, Kim JY. Increased absorption of aluminium from a normal dietary intake in dementia. J Inorg Biochem 1998; 69: 171-6
10. Davenport A, Williams PS, Roberts NB, Bone JM. Sepsis: a cause of aluminum release from tissue stores associated with acute neurological dysfunction and mortality. Clin Nephrol 1988; 30: 48-51
11. Tarng DC, Huang TP. Recombinant human erythropoietin resistance in iron-replete hemodialysis patients: role of aluminum toxicity. Am J Nephrol 1998; 18: 1-8
12. Canteros A, Diaz-Corte C, Fernandez-Martin JL, Gago E, Fernandez-Merayo C, Cannata J. Ultrafiltrable aluminium after very low doses of desferrioxamine. Nephrol Dial Transplant 1998; 13: 1538-42
13. Drueke TB. Intestinal absorption of aluminium in renal failure. Nephrol Dial Transplant 2002; 17(Suppl 2): 6-13
14. Di Paolo N, Masti A, Comparini IB, et al. Uremia, dialysis and aluminium. Int J Artif Organs 1997; 20: 547-52
15. Bellia JP, Newton K, Davenport A, Birchall JD, Roberts NB. Silicon and aluminium and their inter-relationship in serum and urine after renal transplantation. Eur J Clin Inv 1994; 24: 703-10
16. McCauley J, Sorkin MI. Exacerbation of aluminium encephalopathy after treatment with desferrioxamine. Nephrol Dial Transplant 1989; 4: 110-4
17. D'Haese PC, Couttenye MM, Goodman WG, et al. Use of the low-dose desferrioxamine test to diagnose and differentiate between patients with aluminium-related bone disease, increased risk for aluminium toxicity, or aluminium overload. Nephrol Dial Transplant 1995; 10: 1874-84
18. Barata JD, D'Haese PC, Pires C, Lamberts LV, Simoes J, De Broe ME. Low-dose (5 mg/kg) desferrioxamine treatment in acutely aluminium-intoxicated haemodialysis patients using two drug administration schedules. Nephrol Dial Transplant 1996; 11: 125-32
19. Yaqoob M, Ahmad R, McClelland P, et al. Resistance to recombinant human erythropoietin due to aluminium overload and its reversal by low dose desferrioxamine therapy. Postgrad Med J 1993; 69: 124-8
20. Exley C, Birchall JD. The cellular toxicity of aluminium. J Theor Biol 1992; 159: 83-98
21. Altmann P, Dhanesha U, Hamon C, Cunningham J, Blair J, Marsh F. Disturbance of cerebral function by aluminium in haemodialysis patients without overt aluminium toxicity. Lancet 1989; 2: 7-12